Pegvaliase + Methotrexate for PKU

This trial aims to determine if combining methotrexate with Palynziq (pegvaliase) can help individuals with PKU better tolerate their treatment and enhance its effectiveness. PKU is a condition where the body cannot break down a specific amino acid, leading to health issues. The trial seeks adults who either have not tried Palynziq or have used it for at least 24 weeks without dose increases but still exhibit high levels of the amino acid in their blood. Participants must be in generally good health and willing to try both medications together. As a Phase 4 trial, this research focuses on understanding how this FDA-approved and effective treatment can benefit more patients.

Participants must stop taking other PKU treatments besides Palynziq, as these are not allowed in the study.

Research has shown that pegvaliase is generally safe for humans, though it can cause some reactions. Approximately 72% of people using pegvaliase have experienced hypersensitivity reactions, which resemble allergic reactions but are less severe than anaphylaxis. These reactions vary among individuals, so managing them according to their severity is crucial. The FDA has approved pegvaliase to help adults with PKU lower their blood phenylalanine (Phe) levels, supporting its safety.

Methotrexate has undergone successful testing in humans, indicating a known safety profile. However, specific side effects when combined with pegvaliase are not detailed here.

Most treatments for phenylketonuria (PKU) focus on strict dietary restrictions and enzyme replacement therapies like sapropterin dihydrochloride. But Pegvaliase, the study drug, works differently by using an enzyme called phenylalanine ammonia-lyase, which breaks down phenylalanine directly in the blood. This unique mechanism can significantly lower blood phenylalanine levels, which is crucial for patients who struggle to manage their condition with diet and existing therapies alone. Researchers are excited about combining Pegvaliase with Methotrexate because Methotrexate may enhance the tolerability and effectiveness of Pegvaliase, offering a potentially more robust treatment option for those with uncontrolled PKU.

Research has shown that pegvaliase lowers blood phenylalanine (Phe) levels in people with phenylketonuria (PKU). In one study, 71.3% of adults using pegvaliase achieved safe Phe levels of 600 μmol/L or less. Another study found that adolescents experienced an average drop of 49.7% in their blood Phe levels. Among those using pegvaliase for extended periods, 87% saw a 20% reduction in Phe levels within a year, increasing to 93.5% after two years. This trial will evaluate the combination of pegvaliase with methotrexate. Participants in the "Palynziq naïve" arm will start with methotrexate alone before adding pegvaliase, while those in the "Palynziq experienced" arm will receive both treatments concurrently. This evidence supports pegvaliase's effectiveness in significantly reducing Phe levels in people with PKU.⁵⁶⁷⁸⁹